Pilot project exercise (UQAM)
Optimizing exercise prescription for prostate cancer patients: a pilot study based on participant preferences Nature et objective :A challenge for health professionals is to find adjuvant therapies with a low level of toxicity to combine with standard treatments in order to alleviate the burden of treatment in patients with prostate cancer. Physical activity (PA) is interesting, […]
CAAA617B12203 (PSMACare)
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer Nature and objective :The purpose of this study is to evaluate the efficacy and safety of […]
CAAA617A12402 (Phase 4)
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer Nature and objective :The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks for lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617. The study also […]
PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]
SUMMIT
Real-world clinical study evaluating the performance of the Optilume® BPH catheter system in men with symptomatic benign prostatic hyperplasia (SUMMIT) Nature et objective :Benign prostatic hypertrophy (BPH) is a benign enlargement of the prostate, common in older men and sometimes in younger men as young as 31 years old. Symptoms include urinary problems such as delayed […]
EvoPar
Double-blind, placebo-controlled, randomized, two-cohort phase III study to evaluate AZD5305 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Nature et objective :This is a research project to determine whether the study drug “AZD5305”, given in […]
MK-5684-003
Phase 3, Randomized, Open-Label Trial of MK-5684 Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With a next-generation hormonal agent (NHA) and taxane-based chemotherapy. (MK-5684-003) Nature et objective:This trial is testing MK-5864 in men with metastatic castration-resistant prostate cancer (mCRPC). This trial will compare MK-5684 to abiraterone acetate […]
PROSTEP-002
Detection and monitoring of metastases using PET/CT imaging using the 18F-DCFPyL (PyL) tracer, in patients starting enzalutamide to treat castration-resistant prostate cancer with small number of metastases, an equivocal result or no metastases on conventional imaging (PROSTEP-002). Nature and objective :This is a study for patients with castration-resistant prostate cancer with a small number of metastases. […]
Ironman
IRONMAN: International registry for men with advanced prostate cancer Nature and objective :This is a registry for people who have been diagnosed with metastatic hormone-sensitive prostate cancer (mCPHS) or non-metastatic (M0) castration-resistant prostate cancer (CRPC) or metastatic (M1). The goal of this research project is to learn more about prostate cancer and: To describe the use […]
